Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Selects Bluebee as Data Processing Partner for MammaPrint, BluePrint IVD Kit

NEW YORK (GenomeWeb) – Agendia announced today that it has signed an agreement to have Dutch genomic data analysis firm Bluebee provide data processing services for a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The kit allows Agendia's MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay to be performed by labs using existing NGS instruments, rather than sending them to the company for centralized processing. It is currently being validated with collaborators in anticipation of a European launch in early 2018.

According to Agendia, Bluebee will help provide secure global access to test kit results, while ensuring that all data complies with local data privacy and residency regulations. Additional terms of the deal were not disclosed.

"When choosing a data processing partner, it was important for us to work with a team that could deliver these results in a highly secure form," Marjolaine Baldo, Agendia's commercial vice president for Europe, the Middle East, and Africa, said in a statement. "We are very pleased to partner with Bluebee as we finalize the development of the MammaPrint BluePrint Kit ahead of European launch."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.